REGENERON PHARMACEUTICALS, INC. financial data

Symbol
REGN on Nasdaq
Location
Tarrytown, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 04 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 439% % -15%
Quick Ratio 80% % 0.78%
Debt-to-equity 29% % 3%
Return On Equity 15% % -4.3%
Return On Assets 12% % -5%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $54,800,000,000 USD -52%
Weighted Average Number of Shares Outstanding, Basic 104,600,000 shares -3.1%
Weighted Average Number of Shares Outstanding, Diluted 108,600,000 shares -5.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $14,342,900,000 USD 0.99%
Research and Development Expense $5,850,200,000 USD 14%
Costs and Expenses $10,765,000,000 USD 5.4%
Operating Income (Loss) $3,577,900,000 USD -10%
Nonoperating Income (Expense) $1,652,800,000 USD 109%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $5,230,700,000 USD 9.4%
Income Tax Expense (Benefit) $725,800,000 USD 98%
Net Income (Loss) Attributable to Parent $4,504,900,000 USD 2.1%
Earnings Per Share, Basic 43.07 USD/shares 5.3%
Earnings Per Share, Diluted 41.48 USD/shares 8.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,118,100,000 USD 25%
Marketable Securities, Current $5,487,100,000 USD -16%
Accounts Receivable, after Allowance for Credit Loss, Current $5,741,100,000 USD -7.6%
Inventory, Net $3,200,800,000 USD 3.7%
Assets, Current $18,021,900,000 USD -3.4%
Deferred Income Tax Assets, Net $4,077,200,000 USD 23%
Operating Lease, Right-of-Use Asset $245,800,000 USD 13%
Intangible Assets, Net (Excluding Goodwill) $1,257,400,000 USD 9.5%
Other Assets, Noncurrent $1,821,200,000 USD 60%
Assets $40,558,700,000 USD 7.4%
Accounts Payable, Current $939,000,000 USD 19%
Employee-related Liabilities, Current $773,000,000 USD 21%
Contract with Customer, Liability, Current $553,000,000 USD -12%
Liabilities, Current $4,368,400,000 USD 11%
Contract with Customer, Liability, Noncurrent $208,700,000 USD 12%
Operating Lease, Liability, Noncurrent $229,000,000 USD 12%
Other Liabilities, Noncurrent $2,018,800,000 USD 28%
Liabilities $9,301,800,000 USD 11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $77,500,000 USD
Retained Earnings (Accumulated Deficit) $35,797,100,000 USD 13%
Stockholders' Equity Attributable to Parent $31,256,900,000 USD 6.5%
Liabilities and Equity $40,558,700,000 USD 7.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,045,100,000 USD -31%
Net Cash Provided by (Used in) Financing Activities $1,089,200,000 USD -2413%
Net Cash Provided by (Used in) Investing Activities $647,500,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $604,000,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,123,700,000 USD 26%
Deferred Tax Assets, Gross $4,079,100,000 USD 20%
Operating Lease, Liability $266,800,000 USD 14%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $4,590,300,000 USD 2.3%
Lessee, Operating Lease, Liability, to be Paid $321,900,000 USD 11%
Operating Lease, Liability, Current $37,800,000 USD 25%
Lessee, Operating Lease, Liability, to be Paid, Year Two $52,300,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year One $52,100,000 USD 21%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $55,100,000 USD -2.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three $48,500,000 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares 0%
Unrecognized Tax Benefits $1,577,900,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year Four $40,300,000 USD 21%
Additional Paid in Capital $13,995,000,000 USD 8.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $126,900,000 USD 11%
Interest Expense $71,100,000 USD 11%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%